MODEL VERDICT
Cidara Therapeutics, Inc. (CDTX) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Jan 11, 2026 | NEUTRAL | 0.19 | $221.38 | CURRENT | — |
| Dec 12, 2025 | NEUTRAL | 0.19 | $220.65 | Below threshold | +0.3% |
| Nov 12, 2025 | NEUTRAL | 0.19 | $107.12 | Below threshold | +106.7% |
| Oct 13, 2025 | NEUTRAL | 0.19 | $116.15 | Below threshold | +90.6% |
| Sep 13, 2025 | NEUTRAL | 0.20 | $65.62 | Below threshold | +236.2% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 3.19 | 3.04 | 1.03 | 7.76 | 2.75 |
| P/B Ratio | 3.19 | 3.04 | 1.03 | 7.76 | 2.75 |
| P/S Ratio | 25.23 | 4.24 | 0.82 | 133.87 | 53.27 |
Insufficient data to determine relative valuation for CDTX.
Fair value could not be computed for CDTX due to insufficient comparable data.
CDTX's current P/E of -8.3x compares to the industry median of 21.4x (48 peers in the group). This represents a -138.6% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
11 analysts cover CDTX with a consensus rating of Buy. The consensus price target is $177.88 (range: $150.00 — $221.50), implying -19.6% upside from the current price. Grade breakdown: Strong Buy (1), Buy (7), Hold (3), Sell (0), Strong Sell (0).
The model confidence score is 49/100, based on: data completeness (0), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for CDTX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.